Ascendis Pharma A/S vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $427.97 (market cap $1.93T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 115.8× Ascendis Pharma A/S's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.9% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TSM | |
|---|---|---|
Market Cap | $16.67B | $1.93T |
Sector | Health | Technology |
52-Week High | $277.18 | $477.57 |
52-Week Low | $189.74 | $227.33 |
Enterprise Value | $17.04B | $1.85T |
Dividend Yield | — | 0.9% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →